NovoCure files for $300 Million IPO

NovoCure, a commercial-stage oncology company developing monotherapy treatments for glioblastoma brain cancer, filed on Monday with the SEC to raise up to $300 million in an initial public offering. The product More...

Tel Aviv U Researcher Stops Tumor Proliferation with Nanoparticples

A new Tel Aviv University study may offer hope to the tens of thousands diagnosed every year with Glioblastoma multiforme (GBM), the most aggressive and devastating form of brain tumor. The disease, always More...